- Home
- AFBI vs STTK Comparison
AFBI vs STTK Comparison
Compare AFBI & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFBI
- STTK
- Stock Information
- Founded
- AFBI 1928
- STTK 2016
- Country
- AFBI United States
- STTK United States
- Employees
- AFBI N/A
- STTK N/A
- Industry
- AFBI Major Banks
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AFBI Finance
- STTK Health Care
- Exchange
- AFBI Nasdaq
- STTK Nasdaq
- Market Cap
- AFBI 123.3M
- STTK 112.6M
- IPO Year
- AFBI N/A
- STTK 2020
- Fundamental
- Price
- AFBI $19.80
- STTK $2.39
- Analyst Decision
- AFBI
- STTK Hold
- Analyst Count
- AFBI 0
- STTK 6
- Target Price
- AFBI N/A
- STTK $2.67
- AVG Volume (30 Days)
- AFBI 3.6K
- STTK 426.9K
- Earning Date
- AFBI 10-24-2025
- STTK 11-13-2025
- Dividend Yield
- AFBI 7.58%
- STTK N/A
- EPS Growth
- AFBI 28.43
- STTK N/A
- EPS
- AFBI 1.08
- STTK N/A
- Revenue
- AFBI $31,417,000.00
- STTK $2,997,000.00
- Revenue This Year
- AFBI N/A
- STTK N/A
- Revenue Next Year
- AFBI N/A
- STTK N/A
- P/E Ratio
- AFBI $18.37
- STTK N/A
- Revenue Growth
- AFBI 4.20
- STTK N/A
- 52 Week Low
- AFBI $17.00
- STTK $0.69
- 52 Week High
- AFBI $22.50
- STTK $2.71
- Technical
- Relative Strength Index (RSI)
- AFBI 57.40
- STTK 68.63
- Support Level
- AFBI $19.62
- STTK $2.29
- Resistance Level
- AFBI $19.83
- STTK $2.71
- Average True Range (ATR)
- AFBI 0.10
- STTK 0.19
- MACD
- AFBI -0.01
- STTK -0.01
- Stochastic Oscillator
- AFBI 89.80
- STTK 72.17
About AFBI Affinity Bancshares Inc. (MD)
Affinity Bancshares Inc is a holding company of Affinity Bank, a federally chartered stock savings bank that offers a variety of deposit accounts, including checking accounts, savings accounts, and certificate of deposit accounts. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate loans, commercial and industrial loans, residential real estate loans, construction and land loans, and consumer loans. It also invests in securities, which consist of mortgage-backed securities and obligations issued by United States government-sponsored enterprises and Federal Home Loan Bank stock.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.